Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baku Acharya

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Expert Opinion on Therapeutic Patents|October 5, 2022
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present)Baku Acharya, Brendan Frett
Future Medicinal Chemistry|February 14, 2022
Targeting TGF-β: triumphs and challengesBaku Acharya, Sayem Miah, Brendan Frett
RSC Medicinal Chemistry|August 4, 2022
FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigmsBaku Acharya, Debasmita Saha, Daniel Armstrong, et al.
European Journal of Medicinal Chemistry|September 18, 2025
Discovery of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRK/PTK6 inhibitorsBaku Acharya, Maha Hanafi, Luke Enemark, et al.
Journal of the American Society for Mass Spectrometry|May 9, 2020
A Combined Infrared Ion Spectroscopy and Computational Chemistry Study of Hydroxyproline IsomersBaku Acharya, W K D N Kaushalya, Jonathan Martens, et al.
British Journal of Haematology|September 22, 2025
Epigenetic dysregulation and therapeutic targeting of RET receptor tyrosine kinase in high-risk KMT2A-rearranged acute myeloid leukaemiaArundhati Chavan, Brendan Frett, Daniel T Armstrong, et al.
Genes|July 27, 2022
Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro GroupKennith Swafford, Baku Acharya, Ying-Zhi Xu, et al.
Bioorganic & Medicinal Chemistry|May 14, 2024
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitorsBaku Acharya, Debasmita Saha, Noemi Garcia Garcia, et al.
Journal of Medicinal Chemistry|August 17, 2021
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical DevelopmentDebasmita Saha, Katie Rose Ryan, Naga Rajiv Lakkaniga, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 24, 2025
Transforming growth factor β receptor 1 and mitogen-activated protein 4 kinase 4 dual inhibitor, TK-850, reduces renal fibrosis in unilateral ureteral-obstructed miceHenry A Palfrey, Samaneh Goorani, Abhishek Mishra, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Expert Opinion on Therapeutic Patents|October 5, 2022
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present)Baku Acharya, Brendan Frett
Future Medicinal Chemistry|February 14, 2022
Targeting TGF-β: triumphs and challengesBaku Acharya, Sayem Miah, Brendan Frett
RSC Medicinal Chemistry|August 4, 2022
FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigmsBaku Acharya, Debasmita Saha, Daniel Armstrong, et al.
European Journal of Medicinal Chemistry|September 18, 2025
Discovery of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRK/PTK6 inhibitorsBaku Acharya, Maha Hanafi, Luke Enemark, et al.
Journal of the American Society for Mass Spectrometry|May 9, 2020
A Combined Infrared Ion Spectroscopy and Computational Chemistry Study of Hydroxyproline IsomersBaku Acharya, W K D N Kaushalya, Jonathan Martens, et al.
British Journal of Haematology|September 22, 2025
Epigenetic dysregulation and therapeutic targeting of RET receptor tyrosine kinase in high-risk KMT2A-rearranged acute myeloid leukaemiaArundhati Chavan, Brendan Frett, Daniel T Armstrong, et al.
Genes|July 27, 2022
Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro GroupKennith Swafford, Baku Acharya, Ying-Zhi Xu, et al.
Bioorganic & Medicinal Chemistry|May 14, 2024
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitorsBaku Acharya, Debasmita Saha, Noemi Garcia Garcia, et al.
Journal of Medicinal Chemistry|August 17, 2021
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical DevelopmentDebasmita Saha, Katie Rose Ryan, Naga Rajiv Lakkaniga, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 24, 2025
Transforming growth factor β receptor 1 and mitogen-activated protein 4 kinase 4 dual inhibitor, TK-850, reduces renal fibrosis in unilateral ureteral-obstructed miceHenry A Palfrey, Samaneh Goorani, Abhishek Mishra, et al.
Pageof 2